Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell.
Melanoma News
MyMelanoma study selected to join NHS DigiTrials initiative
Three projects – including the Oxford-led MyMelanoma study – have been selected to join an NHS initiative, which aims to sign up tens of thousands of volunteers over the next two years to help improve the diagnosis and treatment of cancer patients.
Sunday Brunch with Professor Richard Scolyer AO
Simon visits Australian of the Year 2024 and co-medical director at the Melanoma Institute Australia Professor Richard Scolyer AO for Sunday Brunch.
What Is Known About Psychosocial Wellbeing in Patients With Melanoma In Situ?
A significant gap in research on psychosocial wellbeing among patients newly diagnosed with melanoma in situ (MIS) exists, according to the results of a systematic review published in Melanoma Research.